{"Clinical Trial ID": "NCT00932373", "Intervention": ["INTERVENTION 1:", "Trastuzumab-MCC-DM1 0.3 mg/kg Every 3 weeks", "Trastuzumab-MCC-DM1 0.3 mg/kg administered intravenously (IV) once every 3 weeks", "INTERVENTION 2:", "Trastuzumab-MCC-DM1 0.6 mg/kg Every 3 weeks", "Trastuzumab-CMC-DM1 0.6 mg/kg administered intravenously (IV) once every 3 weeks"], "Eligibility": ["Incorporation criteria:", "Histologically documented, incurable, locally advanced or metastatic breast cancer", "Evaluable or measurable HER2-positive disease", "\u2022 History of progression during or within 60 days of treatment with any previous regimen of chemotherapy containing trastuzumab for breast cancer HER2 positive", "Previous treatment with chemotherapy for MBC", "Number of granulocytes 1,500/\u03bcL, platelet count 100,000/\u03bcL and hemoglobin 9 g/dL", "AST, ALT and alkaline phosphatase 2.5 \u00d7 upper limit of normal (ULN), except for: Patients with hepatic metastases: ALT and AST 5 \u00d7 USN Patients with hepatic and/or bone metastases: alkaline phosphatase 5 \u00d7 ULN", "Serum creatinine level 1.5 mg/dL or creatinine clearance 60 mL/min based on 24-hour urine collection", "Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2", "\u2022 Women of childbearing potential and men should agree to use an effective method of contraception (e.g. hormone, barrier) during treatment under study", "- Exclusion criteria:", "History of major heart disease, unstable angina, myocardial infarction or ventricular arrhythmia requiring medication", "History of hypersensitivity reaction to trastuzumab grade 3", "History of any toxicity to trastuzumab resulting in the definitive cessation of trastuzumab", "\u2022 Symptomatic brain metastases or radiation or surgery for brain metastases within 3 months of the first study", "\u2022 Require additional oxygen for daily activities", "- Peripheral neuropathy grade 2", "A treatment with bisphosphonate for symptomatic hypercalcaemia", "Any chemotherapy, hormone therapy, radiotherapy, immunotherapy or biological therapy for the treatment of breast cancer within 4 weeks of the first study", "Any experimental treatment within 4 weeks of the first study", "Any major surgery within 4 weeks of the first study", "History of clinically symptomatic liver disease, including viral or other hepatitis, alcoholism or cirrhosis", "Pregnancy or lactation", "- Cardiac troponin I 0.2 ng/mL", "- Ejection fraction less than or equal to 50% of the lower limit of normal determined by echocardiogram or MUGA scanning", "A cumulative dose of prior doxorubicin greater than or equal to 360 mg/m2"], "Results": ["Performance measures:", "Percentage of participants with adverse reactions (ADRs), serious adverse reactions (SAEs), AEs with a grade >=3 and treatment-related AEs", "The delay for ARs is the initiation of study therapy up to 30 days after the last treatment administration under study or at the time of initiation of another cancer therapy, which occurs first.", "The time frame for ASAs is initiation of study therapy up to 90 days after the last treatment has been administered under study or at the time of initiation of another cancer therapy, which occurs first.", "Time limit: initiation of study therapy up to 30 or 90 days after the last treatment under study", "Results 1:", "Title of arm/group: Trastuzumab-MCC-DM1 0.3 mg/kg every 3 weeks", "Description of the arm/group: Trastuzumab-CMC-DM1 0.3 mg/kg administered intravenously (IV) once every 3 weeks", "Total number of participants analysed: 3", "Type of measurement: Number", "Unit of measure: % of participants At least 1 AE: 100", "AEs with grade >=3: 33.3", "At least 1 EAS: 33.3", "Treatment-related AEs: 66.7", "Results 2:", "- Arm/group title: Trastuzumab-MCC-DM1 0.6 mg/kg every 3 weeks", "Description of the arm/group: Trastuzumab-CMC-DM1 0.6 mg/kg administered intravenously (IV) once every 3 weeks", "Total number of participants analysed: 1", "Type of measurement: Number", "Unit of measure: % of participants At least 1 AE: 100", "AE grade >=3: 100", "At least 1 EAS: 100", "Treatment-related AEs: 100"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/3 (33.33 per cent)", "- Pain 0/3 (0.00 %)", "- Cellulite 0/3 (0.00 %)", "Influenza 0/3 (0.00 %)", "Osteomyelitis 0/3 (0.00 %)", "Pneumonia 0/3 (0.00 %)", "Fracture of the humerus 0/3 (0.00 %)", "- Brain edema 0/3 (0.00 %)", "Brain haemorrhage 0/3 (0.00 %)", "- Convulsion 0/3 (0.00 %)", "- Dysarthrie 0/3 (0.00 %)", "Hepatic encephalopathy 0/3 (0.00 %)", "Confusion status 0/3 (0.00 per cent)", "Dyspnoea 1/3 (33.33%)", "Adverse Events 2:", "Total: 1/1 (100.00 per cent)", "- Pain 0/1 (0.00 %)", "Cellulite 0/1 (0.00 %)", "Influenza 0/1 (0.00 %)", "Osteomyelitis 0/1 (0.00 %)", "Pneumonia 0/1 (0.00 %)", "Fracture of the humerus 0/1 (0.00 %)", "- Brain edema 0/1 (0.00 %)", "Brain haemorrhage 0/1 (0.00 %)", "Convulsion 0/1 (0.00 %)", "- Dysarthrie 0/1 (0.00 %)", "Hepatic encephalopathy 0/1 (0.00 %)", "Confusion status 0/1 (0.00 per cent)", "- Dyspnoea 0/1 (0.00 %)"]}